Myriad Genetics to Showcase Six AACR Abstracts, Including Two Podium Precise MRD Findings
Myriad Genetics will present six abstracts at AACR 2026, featuring two podium presentations on its ultrasensitive Precise MRD assay, including MONITOR-Breast study data on high-temporal resolution ctDNA dynamics during neoadjuvant breast cancer therapy. Additional presentations include phase II PD-1 blockade plus endocrine therapy trial biomarkers.
1. AACR 2026 Abstract Presentations
Myriad Genetics will present six abstracts at the AACR Annual Meeting on April 17-22 in San Diego, including two podium presentations (CT171 and CT172) on its tumor-informed, ultrasensitive Precise MRD assay. Additional posters will cover analytical validation, polygenic risk scores in high-risk populations, cfDNA fragmentomics and the clinical utility of genomic classifiers.
2. MONITOR-Breast Podium Insights
Dr. Julia Foldi will deliver MONITOR-Breast results (CT171) on high-temporal resolution ctDNA dynamics during neoadjuvant breast cancer therapy, demonstrating distinct response patterns associated with pathological outcomes and highlighting the sensitivity of the Precise MRD test across all treatment phases.
3. Phase II PD-1 Blockade Trial Findings
Dr. Ranjan Upadhyay will present phase II trial data (CT172) combining adjuvant PD-1 blockade with endocrine therapy in hormone receptor positive inflammatory breast cancer, focusing on circulating biomarkers and molecular correlates that inform clinical outcomes and treatment personalization.
4. Expanded Data Portfolio and Booth Exhibition
Myriad will also showcase analytical validation of its ultra-high sensitivity MRD assay, independent validation of polygenic risk scores for triple-negative breast cancer in African American women, fragmentomic cfDNA whole genome analysis, and genomic classifier impact in prostate cancer at booth #3747, alongside demonstrations of Precise MRD, MyRisk, Prolaris and Biopharma service offerings.